TG Therapeutics (TGTX) financial statements
TG Therapeutics reported revenue of $616M in fiscal 2025, up 151.7% a year over 9 years.
Net income was $447M and the operating margin 20.0%, against -51953.3% in 2016.
Free cash flow was -$25M.
The diluted share count rose 229% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from TG Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $152,000 | $152,000 | $152,000 | $152,000 | $152,000 | $7M | $3M | $234M | $329M | $616M |
| Cost of revenue | — | — | — | — | — | $790,000 | $265,000 | $14M | $38M | $101M |
| Gross profit | — | — | — | — | — | $6M | $3M | $220M | $291M | $516M |
| Research and development | $69M | $103M | $159M | $154M | $166M | $223M | $125M | $76M | $94M | $160M |
| Selling, general and admin | $10M | $16M | $15M | $15M | $108M | $128M | $95M | $123M | $154M | $232M |
| Operating income | -$79M | -$119M | -$174M | -$169M | -$274M | -$345M | -$218M | $21M | $42M | $123M |
| Interest expense | — | $845,000 | $877,000 | $5M | $6M | $6M | $10M | $13M | $24M | $27M |
| Pre-tax income | -$78M | -$118,476 | -$173,482 | -$172,871 | -$279,381 | -$348M | -$224M | $13M | $26M | $107M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $390,000 | $2M | -$340M |
| Net income | -$78M | -$118M | -$173M | -$173M | -$279M | -$348M | -$224M | $13M | $23M | $447M |
| EPS (diluted) | -$1.60 | -$1.91 | -$2.30 | -$1.96 | -$2.42 | -$2.63 | -$1.65 | $0.09 | $0.15 | $2.77 |
| Diluted shares | 49M | 62M | 75M | 88M | 115M | 132M | 135M | 149M | 160M | 161M |
| Gross margin | — | — | — | — | — | 88.2% | 90.5% | 94.0% | 88.3% | 83.7% |
| Operating margin | -51953.3% | -78100.0% | -114736.8% | -111220.4% | -179996.1% | -5154.3% | -7839.0% | 8.8% | 12.7% | 20.0% |
| Net margin | -51482.2% | -77944.7% | -114132.9% | -113730.9% | -183803.3% | -5204.1% | -8036.3% | 5.4% | 7.1% | 72.6% |
Balance sheet
Fiscal years, from TG Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $45M | $85M | $69M | $140M | $605M | $350M | $174M | $218M | $311M | $200M |
| Receivables | — | — | — | — | — | $1M | $0 | $51M | $129M | $306M |
| Inventory | — | — | — | — | — | — | $0 | $40M | $110M | $126M |
| Total current assets | $51M | $93M | $79M | $149M | $612M | $331M | $168M | $318M | $566M | $631M |
| Property, plant and equipment | $328,148 | $248,000 | $251,000 | $282,000 | $481,000 | $600,000 | $307,000 | $95,000 | — | — |
| Goodwill | $799,391 | $799,000 | $799,000 | $799,000 | $799,000 | $799,000 | $799,000 | $799,000 | — | — |
| Total assets | $55M | $97M | $84M | $163M | $626M | $380M | $194M | $330M | $578M | $1.1B |
| Total current liabilities | $17M | $28M | $39M | $84M | $88M | $65M | $53M | $54M | $91M | $154M |
| Long-term debt | — | — | $0 | $29M | $8M | $67M | $71M | $100M | $244M | $246M |
| Total liabilities | $19M | $30M | $60M | $124M | $106M | $142M | $135M | $169M | $355M | $415M |
| Shareholders' equity | $36M | $67M | $24M | $39M | $519M | $237M | $59M | $161M | $222M | $648M |
| Net debt | -$25M | -$57M | -$42M | -$84M | -$524M | -$231M | -$31M | $7M | $65M | $166M |
Cash flow
Fiscal years, from TG Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$62M | -$94M | -$129M | -$133M | -$215M | -$296M | -$176M | -$31M | -$41M | -$25M |
| Capital spending | $344,000 | $2,000 | $90,000 | $131,000 | $357,000 | $401,000 | $14,000 | $0 | $45,000 | $214,000 |
| Free cash flow | -$62M | -$94M | -$129M | -$133M | -$215M | -$296M | -$176M | -$31M | -$41M | -$25M |
| Stock-based compensation | $8M | $16M | $13M | $11M | $80M | $61M | $45M | $38M | $43M | $65M |
| Net borrowing | — | — | — | — | — | $70M | $0 | $25M | $245M | $0 |
| Free cash flow margin | -40744.1% | -61685.5% | -84878.3% | -87458.6% | -141357.9% | -4425.7% | -6326.2% | -13.4% | -12.3% | -4.1% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for TGTX.
Open TGTX in InvestinglyQuestions
What was TG Therapeutics's revenue in 2025?
$616M in fiscal 2025, from its 10-K filing.
How much free cash flow does TG Therapeutics generate?
-$25M in fiscal 2025 (operating cash flow minus capital spending).
From TG Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.